INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. & Encourages I...
June 04 2018 - 6:30PM
Business Wire
The Schall Law Firm, a national shareholder rights litigation
firm, announces the filing of a class action lawsuit against Recro
Pharma, Inc. (''Recro Pharma” or ''the Company'') (NASDAQ: REPH)
for violations of §§10(b) and 20(a) of the Securities Exchange Act
of 1934 and Rule 10b-5 promulgated thereunder by the U.S.
Securities and Exchange Commission.
Investors who purchased the Company's shares between July 31,
2017, and May 23, 2018, inclusive (the ''Class Period''), are
encouraged to contact the firm before July 30, 2018.
If you are a shareholder who suffered a loss, click here to
participate.
We also encourage you to contact Brian Schall, or Sherin
Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights
free of charge. You can also reach us through the firm's website
at www.schallfirm.com, or by email
at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the Complaint, Recro Pharma made false and
misleading statements to the marketplace. The Company’s lead
product, IV meloxicam, was unlikely to receive FDA approval due to
lacking sufficient supporting clinical data to demonstrate
significant clinical benefits. As a result, Recro Pharma’s public
statements were materially false and misleading throughout the
class period and did not accurately reflect the results of business
operations and the financial health of the Company. According to
the lawsuit, when accurate information about the Company became
apparent in the market, investors suffered damages.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and rules of
ethics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180604006482/en/
The Schall Law FirmBrian Schall, Esq.Sherin Mahdavian,
Esq.310-301-3335info@schallfirm.comwww.schallfirm.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2023 to Apr 2024